| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Mirum Pharmaceuticals, Inc.
13D/A
MIRM · 604749101
|
6.8% |
1/27/2026
Event 1/23/2026
|
||||
| Frazier Life Sciences IX, L.P. | 5.9% | |||||
| FHMLS IX, L.P. | 5.9% | |||||
| FHMLS IX, L.L.C. | 5.9% | |||||
| Frazier Life Sciences X, L.P. | 0.8% | |||||
| FHMLS X, L.P. | 0.8% | |||||
| FHMLS X, L.L.C. | 0.8% | |||||
| Frazier Life Sciences Public Fund, L.P. | 4.2% | |||||
| FHMLSP, L.P. | 4.2% | |||||
| FHMLSP, L.L.C. | 4.2% | |||||
| Frazier Life Sciences XI, L.P. | 1.8% | |||||
| FHMLS XI, L.P. | 1.8% | |||||
| FHMLS XI, L.L.C. | 1.8% | |||||
| Frazier Life Sciences XII, L.P. | 0.1% | |||||
| FHMLS XII, L.P. | 0.1% | |||||
| FHMLS XII, L.L.C. | 0.1% | |||||
| James N. Topper | 6.7% | |||||
| Patrick J. Heron | 6.8% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.